Bergen, Norway, 9 December 2020 – Extraordinary General Meeting in BerGenBio ASA is being held virtually today 9 December 2020 at 16:00 hours (CET). Information on how to join the meeting: Webcast link: https://web.lumiagm.com/?fromUrl=127403163 Meeting ID: 127-403-163 Please note you must be logged in online before the meeting starts to be able to vote on … Read more
Bergen, Norge – 8 desember 2020: BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, kunngjør i dag at den første pasienten har blitt rekruttert med bemcentinib i den kliniske COVID-19 ACCORD studien finansiert av UK Research and Innovation (UKRI). … Read more
Bergen, Norway – 8[th] December 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the first patient has been enrolled with bemcentinib in the UK Research and Innovation (UKRI) funded COVID-19 ACCORD clinical study. The ACCORD study is a multicentre, seamless, Phase … Read more
· Klinisk nyttefrekvens på 73% rapportert i pasienter med AML tilbakefall i andrelinje (2L). Total responsrate ORR 45%, Komplett respons (CR/CRi) rate på 36% Median behandlingsvarighet over 6 måneder med noen pasienter gjenværende på studien Bergen, Norge – 6. desember 2020: BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere … Read more
Clinical benefit rate of 73% reported in second line relapsed AML patients. Overall Response OOR 45%, CR/CRi rate of 36% Median treatment duration exceeding 6 months with some patients remaining on study Bergen, Norway, 6 DECEMBER 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, … Read more
Bergen, Norway, 3[ ]December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that members of the management team will present the company at the following virtual conferences: The Nordic-American Life Science Conference Global Markets Day section Date: 3[rd] December 2020 … Read more
Bergen, Norway, 30 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has been accepted for a poster presentation at the 62[nd] Annual American Society of Hematology (ASH) Meeting, being held virtually from 5-8 December 2020. The poster will … Read more
Bergen, Norge – 24 november 2020: BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, kunngjør i dag at den første pasienten har blitt rekruttert i selskapets fase-II klinisk studie (BGBC020), som vurderer effekten og sikkerheten til bemcentinib for behandling … Read more
Bergen, Norway – 24[th] November 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the first patient in India has been enrolled in the company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of … Read more
Bergen, Norge, 18 November 2020 – Det blir herved meldt at en ekstraordinær generalforsamling i BerGenBio ASA vil bli avholdt virtuelt 9 desember 2020 klokken 16.00 (CET). Innkalling, påmeldingsskjema og fullmakt er vedlagt dette skrivet. Innkallingen vil bli sendt til alle registrerte aksjonærer og er tilgengelig på https://www.bergenbio.com/investors/general- meetings/ (https://www.bergenbio.com/investors/general-%20meetings/) Alle aksjonærer oppfordres til å utøve sine … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.